GELTAMO-IPI在Hans算法定义的弥漫大B细胞淋巴瘤细胞起源亚型中的差异预后影响
本研究探讨GELTAMO-IPI在Hans算法定义的GCB与非GCB弥漫大B细胞淋巴瘤亚型中的预后影响。839例患者有细胞起源数据(380例GCB,459例非GCB),780例同时有GELTAMO-IPI和细胞起源数据(353例GCB,427例非GCB)。两亚型5年总生存无差异,Cox模型显示GELTAMO-IPI风险组与细胞起源亚型存在交互作用(P=0·005),GELTAMO-IPI在非GCB亚型中识别出真正预后不良组。
要点
- 两亚型5年总生存无差异。
- GELTAMO-IPI风险组与细胞起源亚型存在交互作用(P=0·005)。
- GELTAMO-IPI在非GCB亚型中识别出真正预后不良组。
核心结论
- GELTAMO-IPI在GCB与非GCB亚型中具有不同预后效应,并在非GCB亚型中识别出真正预后不良组。
研究设计与样本
- 研究纳入接受免疫化疗的弥漫大B细胞淋巴瘤患者,839例有细胞起源数据(380例GCB,459例非GCB),780例同时有GELTAMO-IPI和细胞起源数据(353例GCB,427例非GCB)。
- 采用多因素Cox回归模型,纳入GELTAMO-IPI风险组、细胞起源亚型及其乘积项,评估两变量间交互作用。
主要发现
- 两亚型5年总生存无差异。
- Cox模型显示GELTAMO-IPI风险组与细胞起源亚型存在交互作用(P=0·005)。
- GCB亚型中,低危、低中危和合并高中危+高危的5年总生存分别为100%、75%和52%。
- 非GCB亚型中,低危、合并低中危+高中危和高危的5年总生存分别为97%、82%和35%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Grupo Español de Linfomas y Trasplantes de Médula Ósea International Prognostic Index (GELTAMO-IPI) stratifies four risk groups in diffuse large B cell lymphoma (DLBCL) patients treated with immunochaemotherapy: low (LR), low-intermediate (LIR), high-intermediate (HIR), and high (HR). The present study explores the effect of GELTAMO-IPI in the DLBCL subtypes defined by the immunohistochaemistry-based Hans algorithm, Germinal Centre B (GCB) and non-GCB. A multivariate Cox regression model including GELTAMO-IPI risk groups, cell of origin (COO) subtypes and their product was developed to evaluate interaction between the two variables. The COO subtype was available in 839 patients (380 GCB; 459 non-GCB) and both the GELTAMO-IPI and the COO subtype in 780 (353 GCB; 427 non-GCB). There were no differences in 5-year overall survival (OS) between the two subtypes. The Cox model revealed interaction between the GELTAMO-IPI risk groups and the COO subtypes (P = 0·005), indicating that GELTAMO-IPI has a different effect in the two subtypes. Three risk groups were stratified in both COO subtypes: in the GCB subtype, LR, LIR and the combined HIR+HR had 5-year OS of 100%, 75% and 52%, respectively. In the non-GCB subtype, LR, the combined LIR+HIR and HR had a 5-year OS of, 97%, 82% and 35% respectively. GELTAMO-IPI identifies a genuine poor outcome group of patients in the DLBCL non-GCB subtype.
引用
- Montalbán C, Díaz-López A, Martín A, et al. Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm. Br J Haematol. 2018. PMID: 29978453. doi:10.1111/bjh.15446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。